List of Arcapta Neohaler drug patents

Arcapta Neohaler is owned by Novartis.

Arcapta Neohaler contains Indacaterol Maleate.

Arcapta Neohaler has a total of 2 drug patents out of which 0 drug patents have expired.

Arcapta Neohaler was authorised for market use on 01 July, 2011.

Arcapta Neohaler is available in powder;inhalation dosage forms.

Arcapta Neohaler can be used as the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

The generics of Arcapta Neohaler are possible to be released after 11 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

ARCAPTA NEOHALER family patents

2

Japan

2

European Union

1

Israel

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Slovenia

1

Russia

1

Morocco

1

Norway

1

Germany

1

United States

1

Argentina

1

Brazil

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Peru

1

Korea, Republic of

1

Poland

1

Taiwan, Province of China

1

United Kingdom

1

China

1

Ecuador

1

Canada

1

Tunisia

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in